You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Practical Considerations for Recognizing, Diagnosing, and Managing Non-Cystic Fibrosis Bronchiectasis: A Care Team Forum®

  • Authors: Doreen J. Addrizzo-Harris, MD (Chair); Charles L. Daley, MD; Anne E. O’Donnell, MD
  • CME Released: 6/28/2022
  • Valid for credit through: 6/27/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for pulmonary, infectious diseases, radiology, and primary care clinicians who manage patients with non-cystic fibrosis bronchiectasis (NCFBE).


The goal of this activity is to raise awareness of and educate on the diagnostic testing and multifaceted management essential for patients with NCFBE. Clinicians will learn about the important role of neutrophil serine proteases (NSPs) in NCFBE pathophysiology, including emerging therapies that target neutrophilic inflammation. An experienced patient with NCFBE shares her difficult diagnostic and therapeutic journey and provides impactful insights for clinical care.


Upon completion of this activity, participants should be better able to: 

  • Apply current criteria for diagnosing non-cystic fibrosis bronchiectasis (NCFBE)

  • Employ current management strategies for the treatment of patients with NCFBE

  • Examine the role of neutrophil serine proteases (NSPs) in the pathophysiology of NCFBE

  • Assess the potential impact of emerging therapies targeting NSPs on the treatment of NCFBE


Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.


  • Doreen J. Addrizzo-Harris, MD (Chair)

    Professor, Medicine  
    Associate Director, Clinical and Academic Affairs  
    Director, NYU Bronchiectasis/NTM Program  
    NYU Grossman School of Medicine  
    New York, NY


    Doreen J. Addrizzo-Harris, MD, has the following relevant financial relationships: 
    Received Grants/Research Support paid to NYU Langone Health:  Boehringer Ingelheim; Hill-Rom; Insmed; Zambon

  • Charles L. Daley, MD

    Chief, Division of Mycobacterial & Respiratory Infections 
    Professor, Medicine 
    National Jewish Health 
    Denver, CO


    Charles L. Daley, MD, has the following relevant financial relationships: 
    Served as an Advisor or Consultant for:  AN2; AstraZeneca; Genentech; Insmed; Legochem Bio; Matinas; Paratek; Pfizer; Renovion; Spero
    Received Grants for Clinical Research from:  AN2; Beyond Air; BugWorks; Insmed; Paratek; Renovion

  • Anne E. O’Donnell, MD

    Professor, Medicine 
    Chief, Division of Pulmonary, Critical Care and Sleep Medicine 
    The Nehemiah and Naomi Cohen Chair in Pulmonary Disease Research 
    Georgetown University Medical Center 
    Washington, DC


    Anne E. O’Donnell, MD, has the following relevant financial relationships:
    Received Grants for Clinical Research from:  AstraZeneca; Boehringer Ingelheim; Electromed; Insmed; Parion; Xellia; Zambon

Patient participating in this activity has no relevant financial relationship(s). 
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.  

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies. 

Disclosure of Unlabeled Use   
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. 

Accreditation Statements

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


    For Physicians

  • RMEI Medical Education, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Practical Considerations for Recognizing, Diagnosing, and Managing Non-Cystic Fibrosis Bronchiectasis: A Care Team Forum®

Authors: Doreen J. Addrizzo-Harris, MD (Chair); Charles L. Daley, MD; Anne E. O’Donnell, MDFaculty and Disclosures

CME Released: 6/28/2022

Valid for credit through: 6/27/2023


Pre-Assessment Questions

  • Print